학술논문

Dexamethasone and potassium canrenoate alleviate hyperalgesia by competitively regulating IL‐6/JAK2/STAT3 signaling pathway during inflammatory pain in vivo and in vitro
Document Type
Report
Source
Immunity, Inflammation and Disease. November 2022, Vol. 10 Issue 11
Subject
Interleukins
Enzyme-linked immunosorbent assay
Inflammation
Liver diseases
Transcription (Genetics)
Central nervous system depressants
Hydrogen
Pain management
Dexamethasone
Chronic kidney failure
Pain -- Care and treatment
Genetic transcription
Language
English
Abstract
INTRODUCTION Dexamethasone (Dexa) is an effective synthetic glucocorticoid acting primarily through the glucocorticoid receptor (GR) and is commonly used as a therapeutic agent that has anti‐inflammatory, antishock, and immunosuppressive effects.[sup.1] [...]
: Background: Dexamethasone (Dexa) and potassium canrenoate (Cane) modulate nociceptive behavior via glucocorticoid receptor (GR) and mineralocorticoid receptor (MR) by two mechanisms (genomic and nongenomic pathways). This study was designed to investigate the Dexa‐ or Cane‐mediated nongenomic and genomic effects on mechanical nociception and inflammation‐induced changes in interleukin‐6 (IL‐6) mediated signaling pathway in rats. Methods: Freund's complete adjuvant (FCA) was used to trigger an inflammation of the right hind paw in male Sprague–Dawley rats. First, the mechanical nociceptive behavioral changes were examined following intraplantar administration of GR agonist Dexa and/or MR antagonist Cane in vivo. Subsequently, the protein levels of IL‐6, IL‐6Rα, JAK2, pJAK2, STAT3, pSTAT3[sup.Ser727], migration inhibitory factor, and cyclooxygenase‐2 were assessed by Western blot following intraplantar injection of Dexa or Cane or the combination. Moreover, the molecular docking studies determined the interaction between Dexa, Cane, and IL‐6. The competition binding assay was carried out using enzyme‐linked immunosorbent assays (ELISA). Results: Administration of Dexa and Cane dose‐dependently attenuated FCA‐induced inflammatory pain. The sub‐additive effect of Dexa/Cane combination was elucidated by isobologram analysis, accompanied by decrease in the spinal levels of IL‐6, pJAK2, and pSTAT3[sup.Ser727]. The molecular docking study demonstrated that both Dexa and Cane displayed a firm interaction with THR[sup.138] binding site of IL‐6 via a strong hydrogen bond. ELISA revealed that Dexa has a higher affinity to IL‐6 than Cane. Conclusions: There was no additive or negative effect of Dexa and Cane, and they modulate the IL‐6/JAK2/STAT3 signaling pathway through competitive binding with IL‐6 and relieves hypersensitivity during inflammatory pain.